BACKGROUND:Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease with poor prognosis and a significant unmet medical need. This study evaluated the safety, pharmacokinetics (PK) and target engagement in the lungs, of GSK3008348, a novel inhaled alpha-v beta-6 (αvβ6) integrin inhibitor, in participants with IPF. METHODS: This was a phase 1b, randomised, double-blind (sponsor unblind) study, conducted in the UK (two clinical sites, one imaging unit) between June 2017 and July 2018 (NCT03069989). Participants with a definite or probable diagnosis of IPF received a single nebulised dose of 1000 mcg GSK3008348 or placebo (ratio 5:2) in two dosing periods. In period 1, safety and PK assessments were performed up to 24 h post-dose; in period 2, after a 7-day to 28-day washout, participants underwent a total of three positron emission tomography (PET) scans: baseline, Day 1 (~ 30 min post-dosing) and Day 2 (~ 24 h post-dosing), using a radiolabelled αvβ6-specific ligand, [18F]FB-A20FMDV2. The primary endpoint was whole lung volume of distribution (VT), not corrected for air volume, at ~ 30 min post-dose compared with pre-dose. The study success criterion, determined using Bayesian analysis, was a posterior probability (true % reduction in VT > 0%) of ≥80%. RESULTS:Eight participants with IPF were enrolled and seven completed the study. Adjusted posterior median reduction in uncorrected VT at ~ 30 min after GSK3008348 inhalation was 20% (95% CrI: - 9 to 42%). The posterior probability that the true % reduction in VT > 0% was 93%. GSK3008348 was well tolerated with no reports of serious adverse events or clinically significant abnormalities that were attributable to study treatment. PK was successfully characterised showing rapid absorption followed by a multiphasic elimination. CONCLUSIONS: This study demonstrated engagement of the αvβ6 integrin target in the lung following nebulised dosing with GSK3008348 to participants with IPF. To the best of our knowledge this is the first time a target-specific PET radioligand has been used to assess target engagement in the lung, not least for an inhaled drug. TRIAL REGISTRATION: clinicaltrials.gov: NCT03069989; date of registration: 3 March 2017.
RCT Entities:
BACKGROUND:Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease with poor prognosis and a significant unmet medical need. This study evaluated the safety, pharmacokinetics (PK) and target engagement in the lungs, of GSK3008348, a novel inhaled alpha-v beta-6 (αvβ6) integrin inhibitor, in participants with IPF. METHODS: This was a phase 1b, randomised, double-blind (sponsor unblind) study, conducted in the UK (two clinical sites, one imaging unit) between June 2017 and July 2018 (NCT03069989). Participants with a definite or probable diagnosis of IPF received a single nebulised dose of 1000 mcg GSK3008348 or placebo (ratio 5:2) in two dosing periods. In period 1, safety and PK assessments were performed up to 24 h post-dose; in period 2, after a 7-day to 28-day washout, participants underwent a total of three positron emission tomography (PET) scans: baseline, Day 1 (~ 30 min post-dosing) and Day 2 (~ 24 h post-dosing), using a radiolabelled αvβ6-specific ligand, [18F]FB-A20FMDV2. The primary endpoint was whole lung volume of distribution (VT), not corrected for air volume, at ~ 30 min post-dose compared with pre-dose. The study success criterion, determined using Bayesian analysis, was a posterior probability (true % reduction in VT > 0%) of ≥80%. RESULTS: Eight participants with IPF were enrolled and seven completed the study. Adjusted posterior median reduction in uncorrected VT at ~ 30 min after GSK3008348 inhalation was 20% (95% CrI: - 9 to 42%). The posterior probability that the true % reduction in VT > 0% was 93%. GSK3008348 was well tolerated with no reports of serious adverse events or clinically significant abnormalities that were attributable to study treatment. PK was successfully characterised showing rapid absorption followed by a multiphasic elimination. CONCLUSIONS: This study demonstrated engagement of the αvβ6 integrin target in the lung following nebulised dosing with GSK3008348 to participants with IPF. To the best of our knowledge this is the first time a target-specific PET radioligand has been used to assess target engagement in the lung, not least for an inhaled drug. TRIAL REGISTRATION: clinicaltrials.gov: NCT03069989; date of registration: 3 March 2017.
Authors: Delphine L Chen; Safia Ballout; Laigao Chen; Joseph Cheriyan; Gourab Choudhury; Ana M Denis-Bacelar; Elise Emond; Kjell Erlandsson; Marie Fisk; Francesco Fraioli; Ashley M Groves; Roger N Gunn; Jun Hatazawa; Beverley F Holman; Brian F Hutton; Hidehiro Iida; Sarah Lee; William MacNee; Keiko Matsunaga; Divya Mohan; David Parr; Alaleh Rashidnasab; Gaia Rizzo; Deepak Subramanian; Ruth Tal-Singer; Kris Thielemans; Nicola Tregay; Edwin J R van Beek; Laurence Vass; Marcos F Vidal Melo; Jeremy W Wellen; Ian Wilkinson; Frederick J Wilson; Tilo Winkler Journal: J Nucl Med Date: 2020-09-18 Impact factor: 11.082
Authors: Paolo Spagnolo; Jonathan A Kropski; Mark G Jones; Joyce S Lee; Giulio Rossi; Theodoros Karampitsakos; Toby M Maher; Argyrios Tzouvelekis; Christopher J Ryerson Journal: Pharmacol Ther Date: 2020-12-24 Impact factor: 13.400
Authors: Willis S Bowman; Chad A Newton; Angela L Linderholm; Megan L Neely; Janelle Vu Pugashetti; Bhavika Kaul; Vivian Vo; Gabrielle A Echt; William Leon; Rupal J Shah; Yong Huang; Christine Kim Garcia; Paul J Wolters; Justin M Oldham Journal: Lancet Respir Med Date: 2022-01-18 Impact factor: 102.642
Authors: Alison E John; Rebecca H Graves; K Tao Pun; Giovanni Vitulli; Ellen J Forty; Paul F Mercer; Josie L Morrell; John W Barrett; Rebecca F Rogers; Maryam Hafeji; Lloyd I Bibby; Elaine Gower; Valerie S Morrison; Yim Man; James A Roper; Jeni C Luckett; Lee A Borthwick; Ben S Barksby; Rachel A Burgoyne; Rory Barnes; Joelle Le; David J Flint; Susan Pyne; Anthony Habgood; Louise A Organ; Chitra Joseph; Rochelle C Edwards-Pritchard; Toby M Maher; Andrew J Fisher; Natasja Stæhr Gudmann; Diana J Leeming; Rachel C Chambers; Pauline T Lukey; Richard P Marshall; Simon J F Macdonald; R Gisli Jenkins; Robert J Slack Journal: Nat Commun Date: 2020-09-16 Impact factor: 14.919